Fiera Capital Corp lowered its stake in shares of Veracyte Inc (NASDAQ:VCYT) by 30.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 163,090 shares of the biotechnology company’s stock after selling 70,861 shares during the quarter. Fiera Capital Corp’s holdings in Veracyte were worth $4,080,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently made changes to their positions in VCYT. Group One Trading L.P. purchased a new stake in shares of Veracyte in the fourth quarter worth $29,000. Essex Investment Management Co. LLC raised its position in shares of Veracyte by 1.4% in the 4th quarter. Essex Investment Management Co. LLC now owns 319,736 shares of the biotechnology company’s stock worth $4,022,000 after purchasing an additional 4,450 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Veracyte by 65,322.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 5,888 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 5,879 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Veracyte by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,544 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 8,235 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its stake in Veracyte by 8.1% in the 4th quarter. Squarepoint Ops LLC now owns 112,141 shares of the biotechnology company’s stock worth $1,411,000 after purchasing an additional 8,434 shares in the last quarter. Institutional investors own 94.32% of the company’s stock.
Shares of Veracyte stock opened at $27.01 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.32 and a quick ratio of 6.06. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -43.56 and a beta of 0.88. Veracyte Inc has a 52-week low of $7.94 and a 52-week high of $28.18.
Veracyte (NASDAQ:VCYT) last issued its earnings results on Tuesday, April 30th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. The business had revenue of $29.53 million during the quarter, compared to analysts’ expectations of $28.20 million. Veracyte had a negative net margin of 15.51% and a negative return on equity of 23.43%. As a group, research analysts predict that Veracyte Inc will post -0.28 EPS for the current year.
A number of analysts have weighed in on VCYT shares. BidaskClub lowered shares of Veracyte from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th. Zacks Investment Research raised shares of Veracyte from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a report on Saturday, May 4th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Veracyte has an average rating of “Buy” and a consensus target price of $16.83.
In other Veracyte news, Chairman Bonnie H. Anderson sold 8,000 shares of Veracyte stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $22.99, for a total value of $183,920.00. Following the completion of the transaction, the chairman now directly owns 103,292 shares of the company’s stock, valued at $2,374,683.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher M. Hall sold 80,000 shares of Veracyte stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $25.12, for a total transaction of $2,009,600.00. Following the completion of the transaction, the insider now directly owns 46,641 shares of the company’s stock, valued at $1,171,621.92. The disclosure for this sale can be found here. Insiders sold 219,000 shares of company stock valued at $5,512,180 over the last ninety days. Corporate insiders own 13.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Veracyte Inc (NASDAQ:VCYT) Shares Sold by Fiera Capital Corp” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://transcriptdaily.com/2019/06/13/veracyte-inc-nasdaqvcyt-shares-sold-by-fiera-capital-corp.html.
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte Inc (NASDAQ:VCYT).
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.